Results 101 to 110 of about 133,919 (116)

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

Journal of Hematology and Oncology, 2023
Aimin Zang, Shenhong Qu, Chuan Jin
exaly  

A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti–PD-1 mAb, in patients with advanced or metastatic solid tumors

Frontiers in Immunology, 2023
Fajun Xie, Zhiyu Huang, Yanjun Xu
exaly  

Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial

Ophthalmology and Therapy, 2023
Siming Zeng, Jilong Hao, Luosheng Tang   +2 more
exaly  

A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk

Acta Pharmacologica Sinica, 2022
Zhen—Lin Zhang, Cheng Qun, Yu Jin-Ming   +2 more
exaly  

Comparison of recombinant human FSH biosimilar QL1012 with Gonal-f® for ovarian stimulation: a phase-three trial

Reproductive BioMedicine Online, 2023
exaly  

A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects

Cancer Chemotherapy and Pharmacology, 2020
Can Guo, Qi Pei, Lu Huang
exaly  

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial

BioDrugs, 2023
Helong Zhang, Runxiang Yang, Minghong Bi   +2 more
exaly  

UBE 2 QL 1 is Disrupted by a Constitutional Translocation Associated with Renal Tumor Predisposition and is a Novel Candidate Renal Tumor Suppressor Gene

Human Mutation, 2013
Christopher J Ricketts, Elena Prigmore, Susan M Gribble   +2 more
exaly  

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects

Frontiers in Pharmacology, 2020
Hong Zhang, Xiaoxue Zhu, Jixuan Sun
exaly  

Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration

Ophthalmology Retina
Attila Vajas, Agnes Kerényi, Jana Stefanickova   +2 more
exaly